drugset / Trial / NCT03613662
A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102
Phase 2
Completed
19 enrolled
Semnur Pharmaceuticals, Inc.
Scilex Pharmaceuticals, Inc. · collabWorldwide Clinical Trials · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, repeat dose study to characterize the pharmacodynamics and safety/tolerability of SP-102 administered by epidural injection.
Timeline
- Start
- 2018-07-13
- Primary completion
- 2019-03-15
- Completion
- 2019-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SP-102 | Unknown | 10 mg | Other |